Search

The World Health Organization (WHO) classified the novel coronavirus (i.e., coronavirus disease 2019 [COVID-19]) as a global public health emergency. COVID-19 threatens to curtail patient access to evidence-based treatment. Medicine is changing, basically due to the limited available resources. In the field of gynecologic oncology, we have to re-design our treatments' paradigm. During COVID-19 pandemic outbreak, the highest priority is to achieve the maximum benefit from less demanding procedures. Extensive procedures should be avoided, in order to reduce hospitalization and postoperative events that might increase the in-hospital spread of the virus. There are ongoing concerns on the use of laparoscopic procedures, related to the possible contamination of the staff working in the operation room. Other minimally invasive techniques, including, vaginal surgery as well as robotic-assisted and isobaric procedures would be preferred over laparoscopy. A fair allocation of resources is paramount adequate treatments. [ABSTRACT FROM AUTHOR]

Kaur and colleagues[1] presented a child with an unusual neurological presentation (longitudinally extensive transverse myelitis) following SARS-CoV-2 infection. Unlike acute presentations due to direct SARS-CoV-2 invasion of the central nervous system (i.e. encephalitis[2]), immune-mediated neurological symptoms may occur when the patient has already cleared the virus and has developed antibodies against it. Along with other well-established infections that trigger facial nerve palsy, we propose to carry out both SARS-CoV-2 swab and serology testing because facila palsy could represent an immune-mediated neurological complication of COVID-19, similar to transverse myelitis and Guillain-Barrè syndrome. [Extracted from the article]